GPX4 and leukemia: Future studies should prioritize validating the expression changes and functional relevance of key proteins within the ubiquitin-proteasome system, ferroptosis pathways, and the autophagy-lysosome axis using established orthogonal methods such as qRT-PCR to confirm mRNA levels and, critically, Western blotting to verify changes at the protein level (e.g., key proteasome subunits, regulators of ferroptosis such as GPX4, and autophagy markers like the LC3-II/LC3-I ratio), thus promoting its clinical translation in leukemia treatment.